Morphea Clinical Trials 2022

Browse 17 Morphea Medical Studies Across 48 Cities

3 Phase 3 Trial · 91 Morphea Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Skin Involvementfor Sclerosis

London, Canada
18+
All Sexes
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.
Waitlist Available
Has No Placebo
17 Morphea Clinical Trials Near Me
Duarte, CA
Québec, Canada
London, Canada
Ann Arbor, MI
More Trial Locations
An interactive map to display trial locations for City of Hope Medical Center, Centre de recherche du CHU de Québec - Université Laval, Rheumatology Clinic, St. Joseph's Health Care, University of Michigan, and 77 more locations.
Most Popular References for Morphea Clinical Trials
Frequency
Citation
Top Hospitals for Morphea Clinical Trials
Location
Active Morphea Clinical Trials
All Time Trials for Morphea
First Recorded Morphea Trial
Trials
University of Michigan, Ann Arbor, Michigan
2
6
2012
Medical University of South Carolina, Charleston, South Carolina
2
8
2000
Hospital for Special Surgery, New York, New York
2
5
2005
Top Treatments for Morphea Clinical Trials
Treatment Name
Active Morphea Clinical Trials
All Time Trials for Morphea
First Recorded Morphea Trial
Trials
Electron Beam Therapy
1
1
2022
Extracorporeal Photopheresis (ECP) with Methoxsalen
1
1
2022
Top Cities for Morphea Clinical Trials
City
Active Morphea Clinical Trials
Top Active Site for Morphea Clinical Trials
Trial List
Boston, Massachusetts
6
Boston University School of Medicine
Houston, Texas
5
The University of Texas Health Science Center at Houston
Most Recent Morphea Clinical Trials
Phase 3 Morphea Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
9/1/2018
Phase 2 & 3
Pediatric Morphea Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Senior Friendly Morphea Clinical Trials

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: August 31st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.